Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, \>=18 years of age;~* locally advanced, inflammatory or early stage invasive breast cancer;~* HER2 positive (HER2+++ by IHC or FISH/CISH+).~Exclusion Criteria:~* metastatic disease (Stage IV) or bilateral breast cancer;~* previous anticancer therapy or radiotherapy for any malignancy;~* other malignancy, other than cancer in situ of the cervix, or basal cell cancer;~* insulin-dependent diabetes;~* clinically relevant cardiovascular disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).